Everest Medicines: Focused on the development and commercialization of globally innovative pharmaceutical products in the Emerging Market.
Everest Medicines: Focused on the development and commercialization of globally innovative pharmaceutical products in the Emerging Market.

About Us

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in the Emerging Market including Asia Pacific territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in the Emerging Market and have a high probability of market approval.     

The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in Asia Pacific territories and with leading global pharmaceutical companies.

Experienced team with a global track record based in key life science hubs in the Asia Pacific territories and the US.

We are determined to address critical unmet medical needs of patients.

News and Events

  • June 22, 2020
    Everest Medicines Announces Positive Results of In Vitro Study of XeravaTM (eravacycline) Against Human Mycoplasmas
  • June 4, 2020
    Everest Medicines Completes US$310 Million Series C Financing
  • April 24, 2020
    Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer
  • April 22, 2020
    Everest Medicines Announces Approval of Clinical Trial Application by China National Medical Products Administration to Initiate China Registration Study of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer
  • April 17, 2020
    Everest Medicines Announces Approval of Xerava™ from the Health Science Authority in Singapore for the Treatment of Complicated Intra-Abdominal Infections
  • April 9, 2020
    Everest Medicines Announces Positive Results from In Vitro Study of Taniborbactam (VNRX-5133) in Combination with Cefepime
  • March 17, 2020
    Everest Medicines Forms Strategic Partnership with Jiashan National Economic and Technological Development Zone and Jiashan SDIC
  • February 20, 2020
    Everest Medicines Appoints Kerry Blanchard, M.D., Ph.D., as Director and Chief Executive Officer

Contact Us

Visit Us

New York

450 Lexington Ave
Suite 39B
New York, NY, 10017
USA

Boston

800 Boylston Street
16th Floor
Boston, MA, 02199
USA

San Diego

12671 High Bluff Drive
Suite 330
San Diego, CA, 92130
USA

Visit Us

New York

450 Lexington Ave
Suite 39B
New York, NY, 10017
USA

San Diego

12671 High Bluff Drive
Suite 330
San Diego, CA, 92130
USA

Boston

800 Boylston Street
16th Floor
Boston, MA, 02199
USA